Bayer/J&J's Xarelto Gets Advisory Cmte. Endorsement In A-Fib, But Not First-Line Use

Cardiovascular and Renal Drugs Advisory Committee votes 9-2, with one abstention, in favor of approval, but more than half the panelists said the indication should be limited to patients who fail other anticoagulant therapy.